中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
6期
814-815
,共2页
哮喘%沙美特罗%丙酸氟替卡松
哮喘%沙美特囉%丙痠氟替卡鬆
효천%사미특라%병산불체잡송
Asthma%Salmeterol%Fluticasone propionate
目的 探讨沙美特罗/氟替卡松干粉剂吸入治疗咳嗽变异型哮喘(CVA)的临床效果及安全性.方法 45例CVA患儿随机分为治疗组23例和对照组22例,治疗组给予沙美特罗/氟替卡松干粉剂吸入,早晚各1次;对照组单纯给予丙酸氟替卡松干粉剂吸入,早晚各1次;两组疗程均为3个月.观察两组治疗前、后临床症状缓解情况、哮喘控制时间、肺功能改善情况和不良反应.结果 治疗后两组咳嗽哮喘症状均有明显改善,治疗后1周治疗组改善情况好于对照组(x2=10.24,P<0.05);治疗后2周、4周时两组差异均无统计学意义(均P>0.05);治疗组哮喘完全控制时间明显短于对照组(t=8.36,P<0.05).治疗后1周、2周、4周,治疗组PEF%均明显高于对照组(t=6.22、7.68、7.95,均P<0.05);治疗后12周,治疗组PEF%与对照组差异无统计学意义(P>0.05).两组无严重不良反应发生.结论 沙美特罗/丙酸氟替卡松干粉吸入治疗CVA安全、有效、使用方便,值得推广.
目的 探討沙美特囉/氟替卡鬆榦粉劑吸入治療咳嗽變異型哮喘(CVA)的臨床效果及安全性.方法 45例CVA患兒隨機分為治療組23例和對照組22例,治療組給予沙美特囉/氟替卡鬆榦粉劑吸入,早晚各1次;對照組單純給予丙痠氟替卡鬆榦粉劑吸入,早晚各1次;兩組療程均為3箇月.觀察兩組治療前、後臨床癥狀緩解情況、哮喘控製時間、肺功能改善情況和不良反應.結果 治療後兩組咳嗽哮喘癥狀均有明顯改善,治療後1週治療組改善情況好于對照組(x2=10.24,P<0.05);治療後2週、4週時兩組差異均無統計學意義(均P>0.05);治療組哮喘完全控製時間明顯短于對照組(t=8.36,P<0.05).治療後1週、2週、4週,治療組PEF%均明顯高于對照組(t=6.22、7.68、7.95,均P<0.05);治療後12週,治療組PEF%與對照組差異無統計學意義(P>0.05).兩組無嚴重不良反應髮生.結論 沙美特囉/丙痠氟替卡鬆榦粉吸入治療CVA安全、有效、使用方便,值得推廣.
목적 탐토사미특라/불체잡송간분제흡입치료해수변이형효천(CVA)적림상효과급안전성.방법 45례CVA환인수궤분위치료조23례화대조조22례,치료조급여사미특라/불체잡송간분제흡입,조만각1차;대조조단순급여병산불체잡송간분제흡입,조만각1차;량조료정균위3개월.관찰량조치료전、후림상증상완해정황、효천공제시간、폐공능개선정황화불량반응.결과 치료후량조해수효천증상균유명현개선,치료후1주치료조개선정황호우대조조(x2=10.24,P<0.05);치료후2주、4주시량조차이균무통계학의의(균P>0.05);치료조효천완전공제시간명현단우대조조(t=8.36,P<0.05).치료후1주、2주、4주,치료조PEF%균명현고우대조조(t=6.22、7.68、7.95,균P<0.05);치료후12주,치료조PEF%여대조조차이무통계학의의(P>0.05).량조무엄중불량반응발생.결론 사미특라/병산불체잡송간분흡입치료CVA안전、유효、사용방편,치득추엄.
Objective To investigate the effect and safety of salmeterol combined with fluticasone propionate dry powder in the treatment of cough variant asthma(CVA).Methods 45 children diagnosed as CVA(aged from 5 to 14 years old)were randomly divided into treatment group(n =23)and control group(n =22).The patients in treatment group were treated with salmeterol combined with fluticasone propionate every morning and evening,while the control group were only given fluticasone propionate every morning and evening.The two groups were treated for 3 months.The change of clinical symptoms,asthma control time,lung function (PEF% pred) and adverse reactions were observed before and after treatment.Results Cough was relieved in most cases after treatment in both groups,but the improvement was more significant in treatment group than that in control group 1 week after treatment( x2 =10.24,P < 0.05).However,there were no significant differences of clinical efficacy between two groups 2 weeks later( P >0.05).Full control time of asthma was in treatment group,which was significantly earlier than the control group( t =8.36,P < 0.05 ).PEF% pred was shorter significantly higher in two groups after 1 week,2 and 4 weeks,but the improvement was more significant in treatment group than that in control group( t =6.22,7.68,7.95,all P < 0.05 ).1 case of headache in treatment group was relieved by symptomatic treatment and no other serious adverse events occured.Conclusion Salmeterol combined with fluticasone propionate was safe,effective,easy to use for treating CVA.